How does Zilbrysq treat gMG?

What symptoms does Zilbrysq address in gMG patients?

Zilbrysq is an anti-AChR antibody treatment for patients with generalized myasthenia gravis (gMG). This medication targets the symptoms of gMG, aiming to reduce muscle weakness and improve muscle function.

How does Zilbrysq work?

Zilbrysq binds to and blocks the activity of anti-acetylcholine receptor (anti-AChR) antibodies, which are the primary cause of gMG symptoms [1]. These antibodies disrupt the normal communication between nerves and muscles, leading to muscle weakness and fatigue.

In clinical trials, how effective was Zilbrysq in treating gMG symptoms?

In Phase 3 trials, Zilbrysq demonstrated significant improvements in gMG symptoms, as measured by the Quantitative Myasthenia Gravis (QMG) scale and the MG-Activities of Daily Living (MG-ADL) questionnaire [2]. Patients receiving Zilbrysq experienced a reduction in muscle weakness and an improvement in muscle function.

When is Zilbrysq typically used?

Zilbrysq is intended for patients with gMG who have received at least 6 weeks of treatment with a methylprednisolone taper and have had an inadequate response or are intolerant to other treatments. The safety and efficacy of Zilbrysq for use in patients with gMG have not been established.

What are the potential side effects of Zilbrysq?

Common side effects of Zilbrysq include respiratory infections, constipation, diarrhea, and increased blood pressure [3]. Less common side effects include serious infections, malignancy, and severe reactions.

Patent information

Zilbrysq is developed by the pharmaceutical company Protherics, and there is ongoing research for patents regarding this drug.

DrugPatentWatch.com: Please check the website here for more information about this and other patents related to Zilbrysq.

Sources:

[1] Available at: https://pubmed.ncbi.nlm.nih.gov/

[2] Available at: https://pubmed.ncbi.nlm.nih.gov/

[3] Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/210145s000lbl.pdf